Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tacrolimus Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A known ✓ | P62942 | 19/20 | 0.76 |
| ▸ | FKBP4 | Q02790 | 2/20 | 0.76 |
| ▸ | MLNR | O43193 | 1/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.76 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.76 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.76 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | HTR2B | P41595 | 1/20 | 0.76 |
| ▸ | MTOR | P42345 | 1/20 | 0.76 |
| ▸ | FKBP1B | P68106 | 1/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.76 |
| ▸ | PPP3CA | Q08209 | 1/20 | 0.76 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.76 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tacrolimus Anhydrous SCHEMBL14922443 | 0.87 | FKBP1A (1.00) | FKBP1AFKBP4MLNRNR1I2ABCB11 | |
| Tacrolimus Anhydrous SCHEMBL20932169 | 0.87 | FKBP1A (1.00) | FKBP1AFKBP4MLNRNR1I2ABCB11 | |
| Tacrolimus Anhydrous SCHEMBL22382731 | 0.87 | FKBP1A (1.00) | FKBP1AFKBP4MLNRNR1I2ABCB11 | |
| Tacrolimus Anhydrous SCHEMBL23565408 | 0.87 | FKBP1A (1.00) | FKBP1AFKBP4MLNRNR1I2ABCB11 | |
| Tacrolimus Anhydrous SCHEMBL21653621 | 0.87 | FKBP1A (1.00) | FKBP1AFKBP4MLNRNR1I2ABCB11 | |
| Tacrolimus Anhydrous SCHEMBL24172830 | 0.87 | FKBP1A (1.00) | FKBP1AFKBP4MLNRNR1I2ABCB11 | |
| Tacrolimus Anhydrous SCHEMBL20793532 | 0.87 | FKBP1A (1.00) | FKBP1AFKBP4MLNRNR1I2ABCB11 | |
| Tacrolimus Anhydrous SCHEMBL23424493 | 0.87 | FKBP1A (1.00) | FKBP1AFKBP4MLNRNR1I2ABCB11 | |
| Tacrolimus Anhydrous SCHEMBL20793344 | 0.87 | FKBP1A (1.00) | FKBP1AFKBP4MLNRNR1I2ABCB11 | |
| Tacrolimus Anhydrous SCHEMBL20932174 | 0.87 | FKBP1A (1.00) | FKBP1AFKBP4MLNRNR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427178-A2 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | Laboratory Skin Care, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129819-A2 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | LABORATORY SKIN CARE, INC. (US) | 2010-11-11 | — | — | WO | disclosed |